American Association for Cancer Research Jan 24 2025 A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial published in Clinical Cancer Research , a journal of the American Association for Cancer Research. Nearly all premalignant cervical lesions and cervical cancers are caused by HPV infection, with HPV16 implicated in the majority of cases." Refika Yigit, MD,